Indication DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

YOU DECIDE: PATIENTS SELF-ADMINISTER AT
HOME OR YOU ADMINISTER IN THE OFFICE1

DUPIXENT is intended for use under the guidance of a healthcare provider. A patient may self-inject DUPIXENT after training in subcutaneous injection technique using the pre-filled syringe. Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use.

DUPIXENT can be administered in the office under the guidance of a healthcare provider if the patient is not an appropriate candidate for self-administration.

Recommended dosing for adult patients with inadequately controlled CRSwNP

NO LOADING DOSE

Important administration instructions

  • Patients should read the Instructions for Use prior to injecting
  • Instruct patients and/or caregivers to administer subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel
  • The upper arm can also be used if a caregiver administers the injection
  • It is important to rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred
  • If a dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to wait until the next dose on the original schedule
  • a 300 mg/2 mL solution.
NOW APPROVED
The DUPIXENT 300 mg
Pre-filled Pen will be
available
by late August 2020!
DUP.20.06.0326

Identify CRSwNP
patients appropriate
for DUPIXENT

View Patients

Reference:

  1. DUPIXENT Prescribing Information.